A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

What Was Tested

In this phase 1 trial, researchers set out to test Semaglutide.

It had three arms (groups): NNC0721-8060 (experimental), Semaglutide (active comparator) and Placebo (placebo comparator).

Participants will receive subcutaneous injection of NNC0721-8060.

Participants will receive subcutaneous injection of semaglutide.

Participants will receive subcutaneous injection of placebo.

The registry classes the interventions as drug.

Who Took Part

The registry lists 142 planned participants were the target.

It was open to people of any sex aged from 18 years up to 55 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Male or female (sex at birth). Age 18-55 years (both inclusive) at the time of signing informed consent. Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: known or suspected hypersensitivity to study intervention(s) or related products; previous randomisation in this study; history of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2026-08-12 with completion listed for 2027-09-23.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Part A: Number of treatment emergent adverse events (TEAE) (time frame: From Day 1 to Day 36). Part B: Number of treatment emergent adverse events (TEAE) (time frame: From Day 1 to Day 57). Part C: Change from baseline in body weight (time frame: From Day 1 to Day 85).

It also tracked 7 secondary outcomes, for example Part A: AUC- Area under the NNC0721-8060 plasma concentration time-curve, Part A: Cmax- Maximum observed plasma concentration of NNC0721-8060, Part B: AUC- Area under the NNC0721-8060 plasma concentration time-curve, Part B: Cmax- Maximum observed plasma concentration of NNC0721-8060, Part C: AUC- Area under the NNC0721-8060 plasma concentration time-curve and Part C: Cmax- Maximum observed plasma concentration of NNC0721-8060.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Semaglutide in 142 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.